Fibrobiologics Stock Price, News & Analysis

FibroBiologics (Nasdaq: FBLG) announced a registered direct offering of 5,227,275 shares at $0.33 per share and a concurrent private placement of unregistered warrants exercisable into up to 5,227,275 shares at $0.33. Gross proceeds from the registered offering are expected to be approximately $1.7 million, before fees and expenses, with potential additional proceeds of ~$1.7 million if warrants are fully exercised on a cash basis. Closing is expected on or about December 16, 2025, subject to customary conditions and stockholder approval for warrant exercise shares. H.C. Wainwright is sole placement agent. Proceeds are intended for working capital and general corporate purposes. The registered shares are offered under an effective Form S-3 registration statement.

FibroBiologics (Nasdaq: FBLG) on December 10, 2025 filed a U.S. patent application titled “Spheroids For Cartilage Repair” for a proprietary fibroblast-derived therapy platform targeting orthopedic and musculoskeletal conditions.

The filing seeks protection for use of fibroblast cells, spheroids, and fibroblast-differentiated chondrocyte spheroids in degenerative disc repair, cartilage repair, and joint restoration. The company noted preclinical studies showing integration with native tissue, extracellular matrix remodeling, and regeneration in disc and joint degeneration models. FibroBiologics reported a portfolio of 270+ patents issued and pending. The company said the patent, if granted, would broaden protection across multiple orthopedic indications.

FibroBiologics (Nasdaq: FBLG) announced it has paid in full the convertible promissory notes issued to Yorkville under the Standby Equity Purchase Agreement (SEPA), eliminating those notes and any further conversions from those tranches.

The SEPA remains in place through December 20, 2026, allowing the company to sell up to an additional $10 million of common stock to Yorkville, subject to customary conditions. Management said the payoff strengthens the balance sheet and supports plans to initiate a Phase 1/2 trial of CYWC628 in early 2026, and to prepare IND submissions for CYPS317 and CYMS101.

FibroBiologics (Nasdaq: FBLG) closed a registered direct offering of 4,477,614 common shares at $0.335 per share for aggregate gross proceeds of approximately $1.5 million on Nov 25, 2025.

In a concurrent private placement the company issued unregistered warrants to purchase up to 4,477,614 shares at an exercise price of $0.335; exercise and sale of shares from those warrants require shareholder approval and, if fully exercised for cash, would generate approximately $1.5 million.

H.C. Wainwright served as exclusive placement agent. Net proceeds are intended for working capital and general corporate purposes.

FibroBiologics (Nasdaq: FBLG) announced a registered direct offering of 4,477,614 common shares at $0.335 per share, expected to raise approximately $1.5 million before fees, with closing expected on or about November 25, 2025.

Concurrently, the company will sell unregistered warrants to purchase up to 4,477,614 shares at an exercise price of $0.335; potential additional gross proceeds if fully exercised equal approximately $1.5 million, subject to stockholder approval and other conditions.

H.C. Wainwright & Co. is the exclusive placement agent. Net proceeds are intended for working capital and general corporate purposes.

FibroBiologics (Nasdaq: FBLG) announced HREC approvals in Australia for a Phase 1/2 trial of its topical allogeneic fibroblast therapy CYWC628 to treat refractory diabetic foot ulcers.

The approval and completed TGA filing enable enrollment of 120 patients at 10 Australian sites. Southern Star Research will manage the multicenter, randomized study evaluating safety, tolerability, and efficacy with low/high dose arms plus standard of care. An interim analysis will occur after a predefined cohort completes six weeks of treatment.

FibroBiologics (Nasdaq: FBLG) closed a registered direct offering on Nov 19, 2025, selling 3,540,000 common shares and pre-funded warrants for 8,570,203 shares at $0.3303 per share/pre-funded warrant (less $0.00001 for each pre-funded warrant).

The purchase price was paid with sovereign .9999 fine gold coins valued at approximately $4,069.18 per ounce, producing gross proceeds of about $4.0 million before expenses. Pre-funded warrants are exercisable at $0.00001 and do not expire.

In a concurrent private placement the company issued unregistered warrants to buy up to 12,110,203 shares at an exercise price of $0.3303, exercisable following stockholder approval and expiring five years after that approval. The company plans to use net proceeds for general corporate purposes, including debt repayment.

FibroBiologics (Nasdaq: FBLG) announced a registered direct offering and concurrent private placement expected to close on or about November 19, 2025. The company agreed to sell 3,540,000 shares and pre-funded warrants to purchase 8,570,203 shares at $0.3303 per share/pre-funded warrant, with aggregate gross proceeds of approximately $4.0 million. Payment will be made in sovereign .9999 fine gold coins, which the company intends to liquidate to U.S. dollars. In the concurrent private placement, the company will issue unregistered warrants to purchase up to 12,110,203 shares at $0.3303, exercisable subject to stockholder approval and expiring five years after such approval.

The company intends to use net proceeds for general corporate purposes, including debt repayment.

FibroBiologics (Nasdaq: FBLG) reported Q3 2025 corporate updates and nine‑month results on Oct 31, 2025. Key program milestones target a Phase 1/2 trial of fibroblast‑based spheroid CYWC628 in diabetic foot ulcers with a planned initiation in Q1 2026 and completion in Q3 2026. The company completed IND‑enabling work for a psoriasis program and advanced a bone marrow organoid platform, plus a patent filing on multipotent cells from fibroblasts.

Financials: R&D rose to $6.6M (nine months) from $3.1M in 2024, G&A was $7.4M, net loss widened to $15.4M, and cash totaled $4.9M at Sept 30, 2025. Manufacturing runs and cGMP completion targeted by end‑2025. The company implemented cost reductions and plans IND submissions for psoriasis and multiple sclerosis programs.